Fig. 3From: Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis(A–D) Forest plot showing the observed outcomes and the estimate of the common and random effect models for Total cholesterol, LDL-C, Lipoprotein a, and Apo lipoprotein B, at Short-term Follow-up (4–12 weeks) [15, 17,18,19,20, 22, 24, 25]Back to article page
